CPIC® Guideline for Simvastatin and SLCO1B1
Most recent guideline publication:
The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1 and Simvastatin-induced Myopathy: 2014 Update (October 2014)
Updates since publication:
No updates on dosing recommendations since publication.
Tables provided in the main manuscript of the guideline:
Table 1. Assignment of likely SLCO1B1 phenotype based on genotype |
Table 2. Dosing recommendations for simvastatin based on SLCO1B1 phenotype |
Supplement to:
The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1 and Simvastatin-induced Myopathy: 2014 Update (October 2014)
Tables and figures included in the supplementa or referenced in the guideline:
Supplemental Figure S1. Pharmacokinetic impact of rs4149056 genotype for several statins |
Supplemental Table S1. Genotypes that constitute the * alleles for SLCO1B1 For an updated version of this table see the SLCO1B1 allele definition table . |
Supplemental Table S2. Association between allelic variants and SLCO1B1 (OATP1B1) function For an updated version of this table see the SLCO1B1 allele functionality table . |
Supplemental Table S3. Observed frequencies for select SLCO1B1 alleles within major race/ethnic or geographic groups For an updated version of this table see the SLCO1B1 frequency table . |
Supplemental Table S4. Detailed distribution of SLCO1B1 allele frequency by race, ethnicity, or geographic groups. For an updated version of this table see the SLCO1B1 frequency table . |
Supplemental Table S5. Evidence linking genotype with phenotype |
Supplemental Table S6. Impact of rs4149056 (V174A) on the pharmacokinetics of various statins |
Supplemental Table S7. FDA Dosing Recommendations for Simvastatin, posted in 2013 |
Supplemental Table S8. Drug(s) that pertain to this guideline |
Supplemental Table S9. Gene(s) that pertain to this guideline For an updated version of this table see the SLCO1B1 gene resource mapping table . |
Supplemental Figure S2. SLCO1B1 Pharmacogenetic Test Result: Clinical Implementation Workflow for EHR |
Supplemental Figure S3. SLCO1B1 Genotype and Simvastatin: Point of Care Clinical Decision Support |
Supplemental Table S10. Example Implementation of this Guideline: Pharmacogenetic Diplotype/Phenotype Summary Entries For an updated version of this table see the SLCO1B1 diplotype-phenotype table . |
Supplemental Table S11. Example Implementation of this Guideline: Point of Care Clinical Decision Support |
aSome of the tables included in the guideline may have been updated on-line, particularly to reflect newly described or newly characterized alleles. These include the gene-specific information tables (https://www.pharmgkb.org/page/pgxGeneRef) that support CPIC guidelines by providing information regarding star (*) allele definitions, allele function, allele frequency by major ethnic groups, translations of diplotype to phenotype, and gene resource mappings.
bThese resources support the adoption of CPIC guidelines into the electronic health record with clinical decision support and provide information that clinical implementers find helpful.
Original publication (July 2012)
- The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-induced Myopathy
- 2012 supplement
This guideline has been endorsed by the American Society of Health-System Pharmacists (ASHP).